No. 23-421
Alfonso Cioffi, et al. v. Google LLC
Response Waived
Tags: 35-usc-251 embodiment-standard federal-circuit original-patent patent patent-disclosure patent-law patent-reissue reissue statutory-interpretation u.s.-industrial-chemicals
Key Terms:
Securities Patent JusticiabilityDoctri
Securities Patent JusticiabilityDoctri
Latest Conference:
2023-11-09
Question Presented (AI Summary)
Should the Antares Pharma, Inc. v. Medac Pharma Inc., 771 F.3d 1354, 1358 (Fed. Cir. 2014) 'exact embodiment' standard for 'original patent' disclosure be overruled as inconsistent with 35 U.S.C. § 251 and this Court's decision in U.S. Industrial Chemicals, Inc. v. Carbide & Carbon Chemicals, Corp., 315 U.S. 668 (1942)?
Question Presented (from Petition)
QUESTION PRESENTED 1. Should the Antares Pharma, Inc. v. Medac Pharma Inc., 771 F.3d 1354, 1358 (Fed. Cir. 2014) “exact embodiment” standard for “original patent” disclosure be overruled as inconsistent with 35 U.S.C. § 251 and this Court’s decision in U.S. Industrial Chemicals, Inc. v. Carbide & Carbon Chemicals, Corp., 315 U.S. 668 (1942)?
Docket Entries
2023-11-13
Petition DENIED.
2023-10-24
DISTRIBUTED for Conference of 11/9/2023.
2023-10-23
Waiver of right of respondent Google LLC to respond filed.
2023-10-16
Petition for a writ of certiorari filed. (Response due November 20, 2023)
Attorneys
Alfonso Cioffi, Melanie Rozman, Megan Rozman and Morgan Rozman
Eric William Benisek — Vasquez Benisek & Lindgren LLP, Petitioner
Eric William Benisek — Vasquez Benisek & Lindgren LLP, Petitioner
Google LLC
Dan L. Bagatell — Perkins Coie LLP, Respondent
Dan L. Bagatell — Perkins Coie LLP, Respondent